Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0801
    +0.0008 (+0.08%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2634
    +0.0012 (+0.10%)
     
  • USD/JPY

    151.1990
    -0.1730 (-0.11%)
     
  • Bitcoin USD

    70,100.62
    -596.70 (-0.84%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

IPO Outlook For The Week: Banks And Biotechs

For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud. IPO dates are expected, not confirmed, at time of publication.

BankFlorida (BFL) will issue 6.2 million shares between $10 and $11 Monday on the Nasdaq. Founded in 2007, the state-chartered community bank closed the last fiscal year with $3 million in revenue and a new loss of $200,000.

Eton Pharmaceuticals, Inc. (ETON) will issue 3 million shares at $6 Tuesday on the Nasdaq. The Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) spinoff was formed in 2017 to develop cheaper alternatives to expensive treatments like H.P. Acthar gel and Xiaflex.

Orchard Rx Ltd (ORTX) will issue more than 13.3 million shares between $14 and $16 Wednesday on the Nasdaq. The London biotech company develops therapies for primary immune deficiencies, inherited metabolic disorders and beta-thalessemia.

Twist Bioscience Corp (TWST) will issue 5 million shares between $14 and $16 Wednesday on the Nasdaq. Based in California, the biotech company applies its silicon-based DNA synthesis platform to clone genes, gene fragments and oligo pools.

Axonics Modulation Technologies (AXNX) will issue 6.7 million shares between $14 and $16 Thursday on the Nasdaq. The medtech company markets sacral neuromodulation technology for urinary and fecal dysfunction.

Meet leaders from the top fintech startups at the Benzinga Fintech Summit next month. Limited tickets available.

Related Links:

5 Reasons Why 2018 Could Be Good For IPO ETFs

Elastic's IPO: What You Need To Know

See more from Benzinga

© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement